| Products/Services Used | Details | Operation |
|---|---|---|
| Peptide Synthesis | For the preparation of HMP-A, the aqueous phase was a mixture of 5 wt.% HAMA with 500 µm C5-24 peptide (Ac-DLQYWYPIWDTHC-NH2, Genscript), 500 µm K-peptide (Ac-FKGGERCGNH2, Genscript), and 10 mm SKP-peptide (Ac-SKPPGTSSC-NH2, Genscript). For the preparation of HMP-B, the aqueous phase was a mixture of 5 wt.% HAMA with 8 mm matrix metalloproteinase 13 (MMP-13) sensitive peptide (Ac-GCPLGMRGC-NH2, Genscript), 500 µm Q-peptide (Ac-NQEQVSPLGGERCG-NH2, GenScript), and 1 wt.% Sulfated Chitosan (SCS). | Get A Quote |
Osteoarthritis (OA) is a typical degenerative disease characterized primarily by the degeneration of cartilage. However, current treatments for cartilage degeneration often lead to the formation of hypertrophic cartilage and fibrocartilage, making it challenging to achieve full-thickness cartilage. Here, dual-modular hydrogel microparticles (dmHMPs) are developed, which enable precise spatio-temporal modulation and dynamic equilibrium between immune responses and cartilage regeneration. dmHMPs can modulate the inflammatory microenvironment of the joint by promoting the polarization of synovial macrophages toward an anti-inflammatory phenotype. Consequently, as inflammation is mitigated, synovium-derived mesench... More
